Heartbeam (BEAT) Investor presentation summary

Market need and clinical gap

• Heart attack detection requires 12-lead ECG data, which is typically only available in clinical settings, leaving a gap for at-home detection and timely intervention.

• Consumer ECG devices, such as wearables, provide limited diagnostic capabilities and cannot reliably detect ischemia or heart attacks outside hospitals.

• Patient delays before hospital arrival are a major driver of poor outcomes and increased costs in cardiac events.

Platform and technology

• The platform offers a cable-free, synthesized 12-lead ECG for arrhythmia assessment, FDA-cleared and protected by 25 patents.

• Utilizes a patented 3D signal collection method, enabling clinical-grade ECG data in a compact, credit card-sized device.

• Personalized algorithms convert 3D signals into physician-ready 12-lead ECG readouts in real time.

• Two form factors: at-home system and on-demand 12-lead patch, both leveraging the core cardiac intelligence platform.

Market opportunity and strategy

• Addresses a $40B cardiac platform opportunity, serving over 50 million at-risk patients across multiple segments.

• Initial focus on concierge and preventive cardiology, targeting 1.5M patients with high willingness to pay and rapid adoption potential.

• Expansion plans include broader patient pay, telehealth, and national chains, leveraging a scalable, cost-effective sales strategy.